In this interview at the Thirteenth Annual Meeting of the Society of Hematologic Oncology (SOHO 2025), Elias Jabbour, MD, leukemia professor at the University of Texas MD Anderson Cancer Center discussed leading a phase 1/2 trial for the potent menin inhibitor bleximenib, an investigational oral therapy used to treat KMT2A-rearranged or NPM1-mutated acute myeloid leukemia (AML).
The study targeted patients with specific mutations, expanding to a phase 2 trial with promising early findings. Dr. Jabbour described the trial’s design, which used a step-up dosing approach to improve safety and effectiveness. Results showed encouraging response rates and lasting benefits for patients. The study also explored combinations with azacitidine and venetoclax.
“Definitely we hope that this drug will receive an approval by the FDA soon for affected populations and in future for frontline indication,” he said. “I’d like to highlight that this drug has very potent activity. It does overcome mutations as well that can lead to resistance to the other menin inhibitors … making bleximenib one of the best in class of the menin inhibitors.”
